Rebecca Taub, M.D. has served as Chief Medical Officer and Executive Vice President, Research & Development, and as a member of our Board of Directors, since July 2016. Previously, Dr. Taub served as Chief Executive Officer and as a member of the Board of Directors of privately-held Madrigal Pharmaceuticals. Dr. Taub served as Vice President, Research, Metabolic Diseases at Hoffmann-La Roche from 2004 to 2008 where Dr. Taub oversaw cardiovascular and metabolic diseases. Before becoming a pharmaceutical executive, Dr. Taub was a tenured Professor of Genetics and Medicine at the University of Pennsylvania.
In a 36-week placebo-controlled phase 2 trial in patients with non-alcoholic steatohepatitis (NASH), treatment with mgl-3196 (resmetirom) significantly reduces atherogenic lipoprotein particles
Event: ESC Congress 2019
Topic: Drug therapy
Session: Risk Factors and Prevention, Cardiovascular Disease in Special Populations
